Related references
Note: Only part of the references are listed.Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome
Marc Laine et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study
Marek Rosiak et al.
CARDIOLOGY JOURNAL (2013)
Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals
Masanori Shimodaira et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Bivalirudin Inhibits Periprocedural Platelet Function and Tissue Factor Expression of Human Smooth Muscle Cells
Wojciech Pepke et al.
CARDIOVASCULAR THERAPEUTICS (2013)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
Dimitrios Alexopoulos et al.
DIABETES CARE (2013)
Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting
Seyed Ebrahim Kassaian et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Morten Wurtz et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry
Caroline Stellbaum et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2012)
Leptin and resistin induce increased procoagulability in diabetes mellitus
Peter Bobbert et al.
CYTOKINE (2011)
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Dominick J. Angiolillo et al.
EUROPEAN HEART JOURNAL (2011)
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis
Daniel Aradi et al.
AMERICAN HEART JOURNAL (2010)
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions
Tobias Geisler et al.
CLINICAL RESEARCH IN CARDIOLOGY (2010)
Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus
S. B. Mortensen et al.
THROMBOSIS RESEARCH (2010)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High glucose enhances transient receptor potential channel canonical type 6-dependent calcium influx in human platelets via phosphatidylinositol 3-kinase-dependent pathway
Daoyan Liu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
High molecular weight adiponectin correlates positively with myeloperoxidase in patients with type 2 diabetes mellitus
P. Bobbert et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
David Erlinge et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone - Is sufficient cholesterol-lowering enough to inhibit platelets?
Michael Piorkowski et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation
Tobias Geisler et al.
DIABETES CARE (2007)
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel
D. Sibbing et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease
DJ Angiolillo et al.
DIABETES (2006)
Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients:: A role of plasma esterases
P Gresner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2006)
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
DJ Angiolillo et al.
DIABETES (2005)
Prevalence of antiplatelet therapy in patients with diabetes
Shaun R. Miller et al.
CARDIOVASCULAR DIABETOLOGY (2005)
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation
DJ van der Heijden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
SR Steinhubl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Soluble CD40L and cardiovascular risk in women
U Schönbeck et al.
CIRCULATION (2001)
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control
JI Osende et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2
U Rauch et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Share Paper
